Novel immunotherapy drugs are used to treat advanced bladder cancer when chemotherapy is no longer working. However, only one in five patients responds to immunotherapy, likely due to biological differences in bladder cancer. Hear Dr. Andreev-Drakhlin—recipient of The ASCO Foundation 2020 Conquer Cancer Young Investigator Award— presents his research plans in using fibroblast growth factor receptor (FGFR) inhibitors for improving the effectiveness of immunotherapy for bladder cancer.
Alexander Andreev-Drakhlin, MD
Medical Oncology Fellow
University of Texas MD Anderson Cancer Center
VIEW ON-DEMAND RECORDING